HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Stacy Markison Selected Research

NBI-12i

9/2007Peripheral administration of the melanocortin-4 receptor antagonist NBI-12i ameliorates uremia-associated cachexia in mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Stacy Markison Research Topics

Disease

6Cachexia
11/2007 - 06/2003
2Parkinson Disease (Parkinson's Disease)
11/2008 - 03/2008
2Weight Gain
05/2008 - 09/2007
2Neoplasms (Cancer)
11/2007 - 06/2005
2Obesity
11/2005 - 06/2003
1Neuroendocrine Tumors (Neuroendocrine Tumor)
04/2022
1Acromegaly
04/2022
1Hypoglycemia (Reactive Hypoglycemia)
01/2022
1Catalepsy
03/2008
1Uremia
09/2007
1Body Weight (Weight, Body)
06/2003

Drug/Important Bio-Agent (IBA)

7Type 4 Melanocortin Receptor (Melanocortin-4 Receptor)IBA
05/2008 - 06/2003
4MelanocortinsIBA
09/2007 - 06/2003
1Somatostatin Receptors (Somatostatin Receptor)IBA
04/2022
1Blood Glucose (Blood Sugar)IBA
01/2022
1Purinergic P1 Receptor AntagonistsIBA
11/2008
1Adenosine (Adenocard)FDA LinkGeneric
11/2008
1Haloperidol (Haldol)FDA LinkGeneric
03/2008
1PiperazineIBA
11/2007
1NBI-12iIBA
09/2007

Therapy/Procedure

1Oral Administration
11/2007
1Therapeutics
06/2003